EGFR and non-small cell lung carcinoma: Consistent with this evidence, dual therapy with NPS-1034 and EGFR-TKI can also prevent or reduce the regrowth of NSCLC tumors in vivo via antiproliferation and apoptosis without apparent adverse effects or weight loss [17,19].